Disease · HP_0040223
Pulmonary hemorrhage
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Pulmonary hemorrhage. Diseases, record HP_0040223. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0040223
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Pulmonary hemorrhage
- Open Targets ID
- HP_0040223
- Other names
- Intrapulmonary haemorrhage, Intrapulmonary hemorrhage, Pulmonary haemorrhage
- Highest stage of its drugs
- Phase 3, for 4 of its 12 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TRANEXAMIC ACID | CHEMBL877 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| DESMOPRESSIN | CHEMBL1429 | Protein | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IBUPROFEN | CHEMBL521 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ACETAMINOPHEN | CHEMBL112 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BERACTANT | CHEMBL1201624 | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets9
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 3 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 3 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5743 | Drugs and targets |
| AVPR1A | Vasopressin receptor | 1 | Vasopressin receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/552 | Drugs and targets |
| AVPR1B | Vasopressin receptor | 1 | Vasopressin receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/553 | Drugs and targets |
| AVPR2 | Vasopressin receptor | 1 | Vasopressin receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/554 | Drugs and targets |
| FAAH | Fatty-acid amide hydrolase 1 | 1 | Anandamide amidohydrolase inhibitor | Unknown | https://conductscience.org/library/genes/2166 | Drugs and targets |
| PLG | Plasminogen | 1 | Plasminogen inhibitor | Phase 3 | https://conductscience.org/library/genes/5340 | Drugs and targets |
| TRPV1 | Transient receptor potential cation channel subfamily V member 1 | 1 | Vanilloid receptor opener | Unknown | https://conductscience.org/library/genes/7442 | Drugs and targets |
Trials9
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00987389 | Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis | Phase 3 | 704 | 2020-05-26 | Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA) | PREDNISOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT04347720 | Canadian National PDA Treatment Study | 1,663 | Patent Ductus Arteriosus, Extreme Prematurity | ACETAMINOPHEN, IBUPROFEN, INDOMETHACIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT07533721 | Ibuprofen vs Expectant Management for hsPDA in Preterm Infants: Retrospective Cohort | 541 | Patent Ductus Arteriosus, Infant, Premature | IBUPROFEN | Its record names the disease | ClinicalTrials.gov | ||
| NCT07481682 | Impact of Inhaled Tranexamic Acid in Pulmonary Hemorrhage in Pediatric Intensive Care Unit | Not applicable | 100 | Tranexamic Acid, Pulmonary Hemorrhage, Pediatric, Intensive Care Unit | TRANEXAMIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT00592566 | Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis | Phase 2/3 | 64 | Leptospirosis | DESMOPRESSIN, DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov | |
| NCT05053867 | A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients | Phase 3 | 60 | Pulmonary Hemorrhage, Cancer | TRANEXAMIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT01860014 | Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage | Not applicable | 20 | Pulmonary Hemorrhage | BERACTANT, PORACTANT ALFA | Its record names the disease | ClinicalTrials.gov | |
| NCT03676023 | Tranexamic Acid Per Inhalation for Treatment of Pulmonary Hemorrhage in Pediatric Patients | 20 | Pulmonary Hemorrhage, MAPCA - Major Aortopulmonary Collateral Artery | TRANEXAMIC ACID | Its record names the disease | ClinicalTrials.gov | ||
| NCT06607016 | A Clinical Trial With KJ103 in Anti-GBM Disease | Phase 2 | 12 | Anti-Glomerular Basement Membrane Disease | CYCLOPHOSPHAMIDE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Plasma Exchange vs No Plasma Exchange: Number of Participants With Sustained Remission | 200 of 352 | 197 of 352 | 704 | NCT00987389 | Trial comparisons |
| Plasma Exchange vs No Plasma Exchange: Composite of i) All-cause Mortality or ii) End-stage Renal Disease | 100 of 352 | 109 of 352 | 704 | NCT00987389 | Trial comparisons |
| Plasma Exchange vs No Plasma Exchange: deaths from any cause | 46 of 352 | 53 of 352 | 704 | NCT00987389 | Trial comparisons |
| Plasma Exchange vs No Plasma Exchange: serious adverse events | 225 of 352 | 224 of 352 | 704 | NCT00987389 | Trial comparisons |
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0040223
GET https://conductscience.org/api/diseases/v1/HP_0040223/drugs